PolyPid Schedules Investor Day Ahead of Key FDA Decision for D-PLEX100
PolyPid Ltd. (PYPD) will host a virtual Investor Day on Oct. 28, 2026. During the event, the company plans to present its 2030 corporate strategy, discuss its product pipeline, and introduce PD01B, a target treatment for diabetic foot infections. PolyPid shares traded down 1.02% at $4.83 following the update.
The announcement comes as the company approaches a key regulatory threshold for its lead product candidate, D-PLEX100. The U.S. Food and Drug Administration is conducting an accelerated review with a decision date set for Nov. 28, 2026. Investors will be watching the upcoming presentation for strategic updates and details regarding potential commercial execution ahead of the FDA ruling.
Key points
- PolyPid Ltd. scheduled a virtual Investor Day for Oct. 28, 2026, to outline its 2030 strategy.
- Lead drug candidate D-PLEX100 is under FDA Priority Review with a decision target date of Nov. 28, 2026.
- The company is introducing PD01B, a pipeline expansion program for diabetic foot infections.
- PolyPid (PYPD) shares fell 1.02% to $4.83 in current trading.
Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org
How we writeDisclaimerQuestions and answers
When is the PolyPid Investor Day?
PolyPid will host its virtual Investor Day on Oct. 28, 2026.
What is the FDA review deadline for D-PLEX100?
The FDA set a target action date of Nov. 28, 2026, under Priority Review.
What is the new program PolyPid is introducing?
PolyPid is introducing PD01B to address diabetic foot infections.